H. Joseph Reiser, Ph.D.
H. Joseph Reiser, Ph.D., has more than 38 years of pharmaceutical and biotech experience in both public and private companies. In large pharma, Dr. Reiser was Corporate Vice President and General Manager, Pharmaceuticals and a member of the Board of Directors for Berlex Laboratories, the U.S. subsidiary of Schering AG (now Bayer AG). During his 17 year tenure at Berlex, Dr. Reiser held numerous senior leadership positions, including President of Schering Berlin’s Venture Corporation, Vice President, Technology and Industry Relations, and Vice President, Drug Development. In the biotech space, Dr. Reiser led or founded 7 biotech companies including 2 NASDAQ-listed public companies, CYTOGEN and Cortendo AB (now StrongBridge) and 5 private companies including Mito Biopharma where he serves as President and CEO and member of the Board. Dr. Reiser has served on numerous Boards and has served as Board Chairman of three companies, more recently Complexa Inc., a clinical stage platform company focusing on fibrosis and inflammation. Dr. Reiser has also served as Chairman of the New Jersey Biotechnology Council from 2001 to 2002 and concluded a six-year tenure as member of the Board and Executive Committee of the Pennsylvania Biotech Association. Dr. Reiser received his Masters and Ph.D. in Physiology from Indiana University School of Medicine and earned a Bachelor of Science degree from Indiana University. Dr. Reiser has been serving Mito BioPharma in various capacity including CEO, Board Member, and Executive Consultant.
Victor Shengkan Jin, Ph.D.
Victor Shengkan Jin, Ph.D. is an internationally recognized expert on research in metabolism and cancer. Dr. Jin is a tenured professor in the Department of Pharmacology at Rutgers University- Robert Wood Johnson Medical School. He also holds joint faculty memberships at the Center for Lipid Research at Rutgers University, the Cardiovascular Institute of New Jersey, and the Cancer Institute of New Jersey. Dr. Jin made seminal discoveries on dissecting the role of autophagy in cancer, in adipose biology, and in metabolic regulation. Dr. Jin’s research has been funded by major grants from the National Institute on Aging (NIH/NIA), National Cancer Institute (NIH/NCI), Department of Defense (DOD), and American Cancer Society (ACS). He has served on many scientific review panels, including NIH and American Cancer Society. Dr. Jin has published important discoveries in various high impact scientific journals including Nature Medicine, Genes and Development, Cancer Cell, PNAS. Dr. Jin is the lead inventor of more than eight important patents. Before joining the faculty of Rutgers University, Dr. Jin received B.S. in Biological Sciences at Tsinghua University, Ph.D. in Pharmacology and Experimental Therapeutics at Cornell University Weill Medical College/Memorial Sloan Kettering Cancer Center, and completed postdoctoral training at Rockefeller University. Dr. Jin is the founder of Mito Biopharma LLC and acting CSO.
David J Augeri, Ph.D.
- Lead inventor of Bristol-Myers Squibb type 2 diabetes drug saxaglipitin
- Inventor of Abbott cancer drug venetoclax
- Medicinal chemistry director, Lexicon
- Prior medicinal chemistry experience in Bristol-Myers Squibb; Abbott; Pfizer
- Co-inventor of Mito BioPharma patents and lead medicinal chemistry advisor
Bin Cao, Ph.D.
Medicinal Chemistry Synthesis
Hanlin Tao, Ph.D.
Biological Screen and Efficacy Testing